Background:Scabies is a highly contagious skin condition caused by an infestation of the human itch mite, Sarcoptes scabiei var. hominis. The present study was conducted to assess the treatment option for scabies. Materials & Methods:36 patients of scabies, of either gender, above 12 years of age were divided into 2 groups of 18 each. Group I received benzyl benzoate (BB) 25% lotion, and group II received tablet ivermectin 200 μg/kg as a single dose. Results: In group I, males were 10 and females were 8 and in group II, males were 9 and females were 9. The common clinical features were itching seen in 18 patients in group I and 17 patients in group II, sores in 7 patients in group I and 4 patients in group II and blisters, or pustules in 11 patients in group I and 14 patients in group II. Cure rate at end of one week in group I was 75% and in group II was 58%. Cure rate at the end of two weeks in group I was 94% and in group II was 100%. Cost effectiveness was INR 1100 for 75 patients in group I and INR 2500 for 58 patients in group II. Cost to treat one patient (INR) was 14.6 in group I and 43.1 in group II. The difference was significant (P< 0.05). Conclusion: The first course of treatment for any scabies sufferer should be BB topically for two weeks. The next course of action for nonresponders should be oral ivermectin once a week for two weeks. Ivermectin the fastest, safer, and most effective way to treat patients, preventing further morbidity and secondary transmission.